Neurocrine price target raised to $130 from $115 at Wedbush

Wedbush raised the firm’s price target on Neurocrine (NBIX) to $130 from $115 and keeps an Outperform rating on the shares. The firm notes the company reported a narrow Ingrezza beat in Q1. However, the more notable result was the Crenessity revenue beat in its first full quarter of launch. While it remains early days, the company reported that 413 total patient enrollment forms have been received thus far. Additionally, the split appears slightly more tilted towards pediatric CAH patients, Wedbush adds.